Leukos Biotech

Executive Summary

Leukos Biotech is a privately held biopharmaceutical company headquartered in Barcelona, Spain, focused on developing novel treatments and diagnostic tools for hematological and solid tumors. Founded in 2016, the company's lead candidate, LB208, is a first-in-class therapy targeting a proprietary pathway. Leukos aims to address significant unmet medical needs in oncology by leveraging its innovative platform. While the company remains in early stages with no disclosed funding or partnerships, its differentiated approach and focus on both liquid and solid tumors position it for potential growth.

Upcoming Catalysts (preview)

• Q2 2026Initiation of Phase I/II clinical trial for LB20840% success
• Q3 2026Presentation of preclinical data at major oncology conference70% success
• H2 2026Strategic partnership or licensing agreement30% success